Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy

Urology

Volumn 57, Issue 6, 2001, Pages 1033-1037

  Roberts, William W ^a   Bergstralh, Erik J ^b   Blute, Michael L ^b   Slezak, Jeffrey M ^b   Carducci, Michael ^a   Han, Misop ^a   Epstein, Jonathan I ^a   Eisenberger, Mario A ^a   Walsh, Patrick C ^a   Partin, Alan W ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER RISK; CONTROLLED STUDY; FOLLOW UP; HIGH RISK POPULATION; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; SCORING SYSTEM; SEMINAL VESICLE; TUMOR MODEL;

ADULT; AGED; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PALPATION; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; TIME FACTORS;

EID: 0035013897     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(01)00978-5     Document Type: Article

References (15)

1. Han M, Partin AW, Pound CR, et al: Long term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the 15-year Johns Hopkins experience. Urol Clin North Am (in press).
2. McCarthy J.F., Catalona W.J., Hudson M.A. Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy early versus delayed treatment . J Urol. 151:1994;1575-1578.
3. Fair W.R., Cookson M.S., Stroumbakis N., et al. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostate cancer Memorial Sloan-Kettering Cancer Center results . Urology. 49:(suppl 3A):1997;46-55.
4. Hegarty N.J., Fitzpatrick J.M., Richie J.P., et al. Future prospects in prostate cancer. Prostate. 40:1999;261-268.
5. Epstein J.I. Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy a diagnosis that should not be made . Am J Surg Pathol. 24:2000;477-478.
6. Bova G.S., Fox W.M., Epstein J.I. Methods of radical prostatectomy specimen processing a novel technique for harvesting fresh prostate cancer tissue and review of processing techniques . Mod Pathol. 6:1993;201-207.
7. Hall G.S., Kramer C.E., Epstein J.I. Evaluation of radical prostatectomy specimens a comparative analysis of various sampling methods . Am J Surg Pathol. 16:1992;315-324.
8. Partin A.W., Piantadosi S., Sanda M.G., et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology. 45:1995;831-838.
9. Bauer J.J., Connelly R.R., Seterhenn I.A., et al. Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer. J Urol. 159:1998;929-933.
10. Veltri R.W., Miller M.C., Partin A.W., et al. Ability to predict biochemical progression using Gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei. Urology. 48:1996;685-691.
11. Krupski T., Petroni G.R., Frierson H.F., et al. Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistries as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate. Urology. 55:2000;743-749.
12. Potter S.R., Miller C., Mangold L.A., et al. Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy. Urology. 54:1999;791-795.
13. Stamey T.A., Yemoto C.Y., McNeal J.E., et al. Prostate cancer is highly predictable a prognostic equation based on all morphological variables in radical prostatectomy specimens . J Urol. 163:2000;1155-1160.
14. Kattan M.W., Wheeler T.M., Scardino P.T. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 17:1999;1499-1507.
15. Blute M.L., Bergstralh E.J., Iocca A., et al. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol. 165:2001;119-125.